There is plenty of evidence that ProGRP (along with NSE, the TM we were unable to measure in plasma) are diagnostic biomarkers for SCLC [11] and other neuroendocrine tumours, but the apparent association with earlier stage is intriguing, especially as most SCLC tested were late stage. Here, ENO2 is linked to neuroendocrine neoplasm.